Wall Street brokerages expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report sales of $1.73 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $2.45 million. Pieris Pharmaceuticals posted sales of $790,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 119%. The firm is expected to issue its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $1.73 million for the current fiscal year, with estimates ranging from $5.20 million to $8.20 million. For the next year, analysts forecast that the business will post sales of $7.00 million per share, with estimates ranging from $5.40 million to $8.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Pieris Pharmaceuticals.

Several analysts have weighed in on the company. HC Wainwright set a $9.00 price target on Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 2nd. BidaskClub cut Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Four investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $9.00.

ILLEGAL ACTIVITY WARNING: “Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Quarterly Sales of $1.73 Million” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/21/pieris-pharmaceuticals-inc-pirs-expected-to-post-quarterly-sales-of-1-73-million.html.

In other news, Director James A. Geraghty acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, with a total value of $48,200.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $48,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Allan Reine acquired 65,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were purchased at an average cost of $4.82 per share, for a total transaction of $313,300.00. Following the completion of the acquisition, the insider now owns 45,000 shares in the company, valued at approximately $216,900. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in PIRS. Renaissance Technologies LLC purchased a new position in shares of Pieris Pharmaceuticals during the 1st quarter valued at about $661,000. Creative Planning raised its holdings in shares of Pieris Pharmaceuticals by 8.3% during the 2nd quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after buying an additional 5,000 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $162,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $292,000. Finally, Rhumbline Advisers purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $184,000. 50.50% of the stock is currently owned by institutional investors.

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) traded down 1.96% on Wednesday, reaching $5.00. The company’s stock had a trading volume of 340,930 shares. Pieris Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $6.58. The stock’s market cap is $221.54 million. The firm’s 50-day moving average price is $5.62 and its 200-day moving average price is $5.62.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.